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OBJECTIVES We sought to evaluate whether pravastatin treatment increases myocardial perfusion, as
assessed by thallium-201 single-photon emission computed tomographic (SPECT) dipyrid-
amole testing, in patients with coronary artery disease (CAD) and average cholesterol levels.
BACKGROUND Previous studies in hypercholesterolemic patients have demonstrated that cholesterol reduc-
tion restores peripheral and coronary endothelium-dependent vasodilation and increases
myocardial perfusion.
METHODS This was a randomized, placebo-controlled study with a cross-over design. Twenty patients
with CAD were randomly assigned to receive 20 mg of pravastatin or placebo for 16 weeks
and then were crossed over to the opposite medication for a further 16 weeks. Lipid and
lipoprotein analysis and dipyridamole thallium-201 SPECT were performed at the end of
each period. The SPECT images were visually analyzed in eight myocardial segments using
a 4-point scoring system by two independent observers. A summed stress score and a summed
rest score were obtained for each patient. Quantitative evaluation was performed by the
Cedars-Sinai method. The magnitude of the defect was expressed as a percentage of global
myocardial perfusion.
RESULTS Total and low density lipoprotein cholesterol levels during placebo were 214 6 29 mg/dl and
148 6 25 mg/dl, respectively. These levels with pravastatin were 170 6 23 mg/dl and 103 6
23 mg/dl, respectively. The summed stress score and summed rest score were lower with
pravastatin than with placebo (7.2 6 2.3 vs. 5.9 6 2.3, p 5 0.012 and 3.2 6 1.6 vs. 2.4 6
2.2, p 5 0.043, respectively). Quantitative analysis showed a smaller perfusion defect with
pravastatin (29.2%) as compared with placebo (33.8%) (p 5 0.021) during dipyridamole
stress. No differences were found at rest.
CONCLUSIONS Reducing cholesterol levels with pravastatin in patients with CAD improves myocardial
perfusion during dipyridamole stress thallium-201 SPECT. (J Am Coll Cardiol 2000;35:
76–82) © 1999 by the American College of Cardiology
Endothelial dysfunction is an early event in the develop-
ment of atherosclerosis. Subjects with a family history of
coronary artery disease (CAD) (1) and those with coronary
risk factors and apparently normal coronary arteries (2,3)
frequently have impaired endothelial function.
High cholesterol levels are associated with abnormal
endothelial vasodilatory capacity (4–7). This defect is
thought to be involved in the pathogenesis of myocardial
ischemia. Cholesterol lowering restores endothelium-
dependent vasodilation in the peripheral and coronary
arteries of hypercholesterolemic patients (8–11), increases
myocardial perfusion as assessed by positron emission to-
mography (PET) (12) and single-photon emission com-
puted tomography (SPECT) (13) and decreases the number
of ischemic episodes detected on 48-h Holter monitoring
(14).
Peripheral vasodilatory function can also be improved in
normolipidemic patients treated with hydroxymethylglu-
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taryl coenzyme A (HMG-CoA) reductase inhibitors (15).
This finding could explain the rapid reduction in cardiovas-
cular morbidity associated with pravastatin treatment in
patients with CAD and average cholesterol levels (16).
It is not known whether lipid reduction in patients with
normal or moderately elevated cholesterol levels could
improve myocardial perfusion. The aim of this study was to
determine whether pravastatin treatment reduces the mag-
nitude of the myocardial perfusion defect in patients with
CAD and average cholesterol levels, as assessed by dipyrid-
amole stress thallium-201 SPECT.
METHODS
Patients. We studied 20 patients with a diagnosis of CAD
(history of documented myocardial infarction or stable
angina pectoris with .50% diameter reduction of at least
one coronary artery on angiography), fasting low density
lipoprotein (LDL) cholesterol ,160 mg/dl at the time of
screening and reversible perfusion defects on dipyridamole
stress thallium-201 SPECT performed during the preced-
ing six months. Patients were excluded if they had taken
lipid-lowering medications during the previous two months
or antioxidant supplements in the preceding three months.
Patients who had percutaneous transluminal coronary an-
gioplasty or coronary artery bypass graft surgery and those
with unstable angina or acute myocardial infarction during
the previous three months were also excluded. None of the
patients had diabetes mellitus or any other significant
disease of the gastrointestinal, renal or endocrine systems.
Study protocol. The study was approved by the Ethics and
Clinical Trials Committee of the Instituto de Salud Carlos
III, and all patients gave written, informed consent.
We compared the effects of pravastatin versus placebo
using a randomized, single-blinded, placebo-controlled,
cross-over design. The study period was 32 weeks. All patients
in the study had LDL cholesterol levels ,160 mg/dl after
four weeks on a 30% fat diet. Patients were randomized to
receive 20 mg of pravastatin in a single nocturnal dose or
placebo for 16 weeks. After completion of this period,
dipyridamole stress SPECT was performed, and patients
were switched to the opposite medication for another 16
weeks. Another SPECT study was carried out at the end of
the second treatment phase. Fasting blood samples were
taken from all patients at the end of both treatment phases
for the determination of total cholesterol, LDL cholesterol,
high density lipoprotein (HDL) cholesterol and triglyceride
levels.
SPECT study. Patients were asked to discontinue anti-
platelet drugs 10 days before the study, angiotensin-
converting enzyme (ACE) inhibitors three days and beta-
blockers, calcium antagonists and nitrates 36 h before the
examination. Caffeine intake was not allowed during the
24-h period preceding testing.
After a 12-h fast, 0.8 mg/kg body weight of dipyridamole
was injected over 6 min. Thallium-201 (2.5 mCi, 92.5 MBq)
was given by bolus injection immediately after dipyridamole
infusion (17). Blood pressure and a 12-lead electrocardio-
gram were monitored and recorded before and after dipyr-
idamole administration. Image acquisition was started
2 min after the radioisotope injection. The rest study was
obtained 4 h later. Another dose of 1.5 mCi (55.5 MBq) of
thallium-201 was injected, and reinjection images were
obtained 20 min later (18).
Thallium-201 SPECT was performed using a single-
head, rotating gamma camera (7500 Orbiter, Siemens)
equipped with a high resolution, parallel-hole collimator.
Thirty-two projections of 20 s each were obtained over a
180° arc in a circular orbit, from the 45° right anterior
oblique to the 45° posterior oblique projection. Images were
reconstructed using a filtered back-projection algorithm,
with a Butterworth filter (cutoff frequency 0.4 cycles/pixel).
Visual assessment was performed by two independent
observers (M.V.G. and F.G.) who had no knowledge of
clinical data or the patients’ identity. Two representative
short-axis slices, one from the basal region and another from
the apical region, were each divided into four segments
(anterior, lateral, inferior and septal). Each of the eight
segments was scored from 0 to 3 (0 5 normal perfusion; 1 5
slightly diminished; 2 5 moderately diminished; 3 5
severely diminished or absence of captation). A summed
stress score and a summed rest score were obtained by
adding the scores of the eight segments of each patient on
stress and rest-reinjection, respectively.
Quantitative analysis was performed according to the
Cedars-Sinai method (19). This method is highly reproduc-
ible and can be used to interpret temporal changes in
myocardial perfusion (20). Three vascular territories were
considered for analysis according to a polar map display of
a commercially available program. The data obtained were
compared with those from a normal data bank. The results
were expressed as a percentage of perfusion defect in the left
ventricle and in each vascular territory. A territory was
considered ischemic if the magnitude of the perfusion defect
exceeded 20%. A global percentage defect was calculated per
patient as the average of the defects in each territory.
Lipid analytical techniques. Serum concentrations of cho-
lesterol and triglycerides were measured by enzymatic meth-
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ANOVA 5 analysis of variance
CAD 5 coronary artery disease
HDL 5 high density lipoprotein
HMG-CoA 5 hydroxymethylglutaryl coenzyme A
LDL 5 low density lipoprotein
PET 5 positron emission tomography
SPECT 5 single-photon emission computed
tomography
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ods. High density lipoprotein cholesterol was determined
after precipitation of serum with phosphotungstic acid (21).
Low density lipoprotein cholesterol was calculated using the
Friedewald formula.
Statistical analysis. Treatment comparisons and period
effects were evaluated by two-way repeated measures anal-
ysis of variance (ANOVA), taking into account the statis-
tical dependence of paired observations in the cross-over
design. To evaluate the presence of carryover effect, we
tested the statistical significance of treatment by period
interactions (22). Data are expressed as the mean value 6
SD. A two-tailed p value ,0.05 was accepted as statistically
significant.
RESULTS
Clinical characteristics. Of the 20 patients (18 men and 2
women) enrolled in the study, two were excluded from
analysis. One patient refused to undergo a second SPECT
study, and the other developed unstable symptoms. The
clinical characteristics of the 18 patients who completed the
study are presented in Table 1. Thirteen had a previous
myocardial infarction. Angiographic confirmation of coro-
nary arteriosclerosis was obtained in 12 patients. One
patient was receiving treatment with ACE inhibitors, 2 with
calcium antagonists, 7 with beta-blockers, 8 with nitrates
and 18 with antiplatelet drugs. There were no changes in
the type or doses of the medications during the study.
Lipid and lipoprotein levels during placebo and pravasta-
tin treatment are presented in Table 2. During the placebo
phase, serum total cholesterol ranged from 153 to 254 mg/dl
and LDL cholesterol from 112 to 169 mg/dl. Body weight
remained stable throughout the study. Except for a lower
systolic blood pressure after dipyridamole injection during
pravastatin treatment, there were no differences in blood
pressure or heart rate before and after dipyridamole during
both phases of the study (data not shown).
Visual assessment. Pravastatin treatment was associated
with a reduction in the magnitude of the perfusion defects.
Summed scores were lower with pravastatin than with
placebo both during dipyridamole stress (5.9 6 2.3 vs. 7.2 6
2.3, p 5 0.012 by ANOVA) and at rest (2.4 6 2.2 vs. 3.2 6
1.6, p 5 0.043 by ANOVA) (Table 3, Fig. 1). Of the 144
segments evaluated (eight segments per each of the 18
patients), scores improved in 37 (26%), worsened in 16
(11%) and remained unchanged in 91 (63%) when prava-
statin was compared with placebo. Figure 2 illustrates the
findings in a representative patient.
Quantitative evaluation. During dipyridamole stress, the
magnitude of the perfusion defect was smaller with prava-
statin (29.2 6 12%) than with placebo (33.8 6 13%) (p 5
0.021 by ANOVA) (Table 3). No differences were observed
between the two treatments groups (pravastatin vs. placebo)
in the rest study (15 6 10% vs. 18.3 6 8%, p 5 0.24 by
ANOVA). Of the 54 territories evaluated (three territories
per each of the 18 patients), 37 (69%) improved and 17
(31%) worsened in perfusion. Considering significant vari-
ations as those above or below 1 SD, 18 (33.3%) of 54
improved and four (7.4%) of 54 worsened in perfusion with
pravastatin. Thirty of the 54 vascular territories had a stress
perfusion defect .20% on placebo and were considered
ischemic. Nine patients had one, 6 patients had two, and 3
patients had all 3 vascular territories that were ischemic.
Perfusion improvement was restricted to these ischemic
territories (magnitude of the perfusion defect 52.8 6 22%
vs. 42.1 6 26% [placebo vs. pravastatin], p , 0.007 by
ANOVA). Pravastatin administration was not associated
with improved perfusion in territories that had normal
Table 2. Lipid Levels During Placebo and Pravastatin Treatment
Placebo Pravastatin Change*
p Value by ANOVA
Treatment
Effect
Period
Effect
Carryover
Effect
Total cholesterol 214 6 29 170 6 23 244.7 6 5.1 , 0.0001 0.81 0.91
HDL cholesterol 40 6 8 42 6 9 2.2 6 1.3 0.13 0.92 0.85
LDL cholesterol 148 6 25 103 6 23 245.4 6 3.7 , 0.0001 0.63 0.25
*Mean change 6 SEM. Other data are presented as mean value (mg/dl) 6 SD.
ANOVA 5 analysis of variance; HDL 5 high density lipoprotein; LDL 5 low density lipoprotein.
Table 1. Clinical Characteristics of Study Patients (n 5 18)
Age (yrs) 60.2 6 6.3 (range 48–68)
Gender (M/F) 16/2
Hypertension 6 (33%)
Smokers 2 (11%)
Ex-smokers 10 (56%)
Nonsmokers 6 (33%)
Previous MI 13 (72%)
Treatments
Antiplatelet drugs 18 (100%)
Beta-blockers 7 (39%)
ACE inhibitors 1 (5.5%)
Calcium antagonists 2 (11%)
Nitrates 8 (44%)
Estrogens 1 (5.5%)
Data are presented as the mean value 6 SD or number (%) of patients.
ACE 5 angiotensin-converting enzyme; F 5 female; M 5 male; MI 5
myocardial infarction.
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perfusion during the placebo phase (magnitude of the
perfusion defect 9.6 6 6% vs. 10 6 8% [placebo vs.
pravastatin], p 5 0.86 by ANOVA). Figure 3 illustrates a polar
map display of the same patient represented in Figure 2.
The improved myocardial perfusion observed with prav-
astatin was not related to age, gender, percentage of total (or
LDL) cholesterol reduction, basal or on-treatment total (or
LDL) cholesterol concentrations or previous myocardial
infarction (data not shown). Period and carryover effects
were not significant for any of the variables analyzed (Table 3).
DISCUSSION
The results of this study show that myocardial perfusion
defects improved after 16 weeks of pravastatin administra-
tion in patients with CAD and average cholesterol levels.
The improved myocardial perfusion was mainly observed
during the dipyridamole stress test. As suggested by previ-
ous reports, the improvement after a short period of
treatment suggests that the benefit is related to functional
rather than anatomic changes (e.g., improved endothelial
function). The study does not indicate, however, whether
the beneficial action of the drug is related to its hypolipi-
demic effects or to its direct action on the endothelial cell.
Endothelial dysfunction, hypercholesterolemia and cho-
lesterol reduction. Endothelial dysfunction is present in
subjects with risk factors for CAD even before structural
changes can be shown in their vessels (1–3). Hypercholes-
terolemic patients have blunted forearm blood flow re-
sponses to nitroprusside and metacholine (5), abnormal
coronary responses to intracoronary infusion of acetylcho-
line (23) and reduced coronary flow reserve (24). Lipid-
lowering therapy can potentially restore coronary and pe-
ripheral endothelium-dependent vasodilation (8–11) and
can increase myocardial perfusion as assessed by PET and
Table 3. Scintigraphic Values During Dipyridamole Stress and at Rest During the Placebo and Pravastatin Phases
Placebo Pravastatin Change*
p Value by ANOVA
Treatment
Effect
Period
Effect
Carryover
Effect
Visual assessment
Summed stress score 7.2 6 2.3 5.9 6 2.3 21.28 6 0.45 0.012 0.33 0.22
Summed redistribution score 3.2 6 1.6 2.4 6 2.2 20.72 6 0.33 0.043 0.66 0.15
Quantitative assessment
Dipyridamole stress 33.8 6 13 29.2 6 12 24.65 6 1.81 0.021 0.76 0.40
Redistribution 18.3 6 8 15 6 10 23.30 6 2.7 0.241 0.98 0.12
*Mean change 6 SEM. Other data are presented as the mean value 6 SD.
ANOVA 5 analysis of variance.
Figure 1. Visual scoring of SPECT images: summed stress score
and summed rest score for each of the 18 patients in the study
during placebo and pravastatin treatment.
Figure 2. Short-axis slices from one representative patient during
dipyridamole stress testing. There is a severe defect in the anterior
and septal segments with placebo (arrows, upper panels) that
partially reverses with pravastatin treatment (arrows, lower pan-
els).
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SPECT (12,13). As previously discussed (12), dipyridamole
increases myocardial perfusion by a direct vasodilatory
effect. This action can precipitate a further increase in
perfusion by a flow-mediated, endothelium-dependent ar-
teriolar vasodilation (25).
Increased blood flow primarily reflects changes in micro-
vascular vasomotion. Hypercholesterolemia affects endothe-
lial function in the microcirculation (26). Enhanced coro-
nary flow after lipid-lowering therapy suggests that small
resistance vessels are involved in the favorable response (10).
Endothelial dysfunction in patients with average choles-
terol levels. An important finding of the study is that
patients with cholesterol levels in the normal to moderately
elevated range can improve their myocardial perfusion with
HMG-CoA reductase treatment. Cholesterol levels in the
high to normal range have been associated with abnormal
endothelial function in healthy subjects (27). Cholesterol
reduction can improve peripheral vasomotion in this group
(15). Our results support the beneficial effects of treatment
with HMG-CoA reductase inhibitors in these subjects and
demonstrate that atherosclerotic coronary vessels can also
improve their functional properties with treatment. En-
hancement of myocardial perfusion was restricted to isch-
emic segments, a finding reported earlier (13). Previous
studies have demonstrated a progressive impairment of
endothelial function in relation to different stages of ath-
erosclerosis (4) and to the extent of local wall thickening
evaluated by intracoronary ultrasound examination (28).
Although the study was not powered to demonstrate
changes in myocardial perfusion at rest, both qualitative and
quantitative evaluations showed a tendency to improve
at-rest perfusion (significant only with the former). These
findings are not surprising as it has been demonstrated that
endothelium-derived nitric oxide is important in the regu-
lation of basal vascular tone (29,30). High cholesterol levels,
in particular, oxidatively modified LDL, can decrease the
synthesis and increase the degradation of nitric oxide
(31,32). The finding that a short-term reduction of previ-
ously considered “normal” cholesterol levels improves myo-
cardial perfusion suggests that even average cholesterol
concentrations negatively influence the vasodilatory capacity
of coronary vessels.
Mechanisms of improved endothelial function by HMG-
CoA reductase inhibitors. The improvement in myocar-
dial perfusion observed during HMG-CoA reductase treat-
ment probably results from the lipid-lowering action of the
drug. This is supported by the fact that other approaches,
including parenteral fat-free nutrition (12), plasmapheresis
(33) and cholestyramine treatment (8), can also improve the
vasodilatory capacity of peripheral and coronary arteries.
However, the beneficial effects observed with HMG-CoA
reductase treatment could also be explained by a direct
action of these drugs on the endothelium, independent of
their action on blood lipids. Supporting this view is the fact
that we could not find a relationship between the magnitude
of cholesterol lowering and the improvement in the perfu-
sion defects, a finding also observed by other investigators
(34). Endothelial dysfunction is associated with impaired
nitric oxide bioavailability (31) and increased release or
activity of endothelin-1 (35); both abnormalities have been
previously described in hypercholesterolemia (36). Statins
can directly increase eNOS (endothelin nitric oxide syn-
thase) expression and nitric oxide production and decrease
endothelin expression in vascular endothelial cells (37,38).
These actions could have a favorable, direct influence on
endothelial function.
Noninvasive evaluation of endothelial dysfunction.
Most studies that have assessed endothelial coronary func-
tion in humans have been invasive. Noninvasive tests that
explore the vasodilatory capacity of coronary arteries are
important in clinical investigation. Positron emission tomo-
graphic studies are expensive and unavailable to many
centers. Thallium-201 SPECT allows the assessment of
myocardial perfusion abnormalities and is highly sensitive to
detect changes in myocardial perfusion associated with
cholesterol reduction.
Figure 3. Polar map display and quantitative analysis of the
SPECT study obtained in the same patient represented in Figure
2. The images were obtained during dipyridamole stress and at
rest, after placebo (upper panel) and pravastatin treatment (lower
panel). The percentage of perfusion defect is represented for each
of three vascular territories (LAD 5 left anterior descending;
RCA 5 right coronary artery; LCX 5 left circumflex) and for the
total left ventricle.
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Study limitations. The improvement of perfusion defects
during pravastatin, although significant, was modest. How-
ever, our data confirm previously reported findings that have
demonstrated that HMG-CoA reductase treatment de-
creases the number of ischemic episodes, as assessed by 48-h
Holter monitoring (14,39), and increases the tolerance to an
exercise test (40).
Conclusions. Administration of pravastatin in patients
with CAD and average cholesterol levels improves myocar-
dial perfusion during dipyridamole stress SPECT. This
favorable action could partially explain the rapid reduction
in cardiovascular morbidity associated with pravastatin
treatment in patients with CAD and average cholesterol
levels.
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